Evelina Grayver, MD
Cardiovascular Disease · Manhasset, NYNPI 1164684270
Payments from drug & device makers
Across 20 payments — averaging $885.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
- Boston Scientific$323
- Medtronic$254
- AstraZeneca$99
- Alnylam Pharmaceuticals Inc.$24
What the payments were for
- Speaking & faculty fees$17,00096%
- Food & beverage$6183%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $17,016 |
| Boston Scientific | 3 | $323 |
| Medtronic | 3 | $254 |
| AstraZeneca | 1 | $99 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$17,000
- Micra$109
- WATCHMAN Access System$107
How this compares
$17,717 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $68,982 |
| EntrestoSacubitril/Valsartan | 21 | $25,802 |
| Praluent PenAlirocumab | 11 | $5,461 |
| Atorvastatin Calcium | 138 | $1,911 |
| Metoprolol Succinate | 75 | $1,611 |
| Ranolazine ErRanolazine | 11 | $1,041 |
| Ezetimibe | 11 | $598 |
| ClopidogrelClopidogrel Bisulfate | 52 | $509 |
| Amlodipine Besylate | 72 | $493 |
| Carvedilol | 46 | $471 |
| Losartan Potassium | 34 | $422 |
| Rosuvastatin Calcium | 44 | $418 |
| Metoprolol Tartrate | 45 | $360 |
| Lisinopril | 32 | $325 |
| Amiodarone Hcl | 12 | $275 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Manhasset
- Bruce RutkinManhasset$2.1M
- Loukas BoutisManhasset$782K
- Benjamin HirshManhasset$467K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.